Zolpidem tartrate, like other sedative-hypnotic drugs, has central nervous system (CNS) depressant effects.Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression.Patients with hepatic insufficiency do not clear the drug as rapidly as normal subjects.
The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated.I’m confident you’ll get the exact the results you’re looking for from all Zen Life products. This gives you 3 months to “test drive” any of our products…But — if for any reason, or no reason at all — you’re not 100% happy, we’ll get all of your money back. Giving you plenty time to make sure you’re left with absolutely no doubts.Patients who develop angioedema after treatment with Zolpidem should not be rechallenged with the drug.Abnormal thinking and behavior changes have been reported in patients treated with sedative/hypnotics, including Zolpidem tartrate.
Although behaviors such as "sleep-driving" have occurred with Zolpidem tartrate alone at therapeutic doses, the co-administration of Zolpidem tartrate with alcohol and other CNS depressants increases the risk of such behaviors, as does the use of Zolpidem tartrate at doses exceeding the maximum recommended dose.